USF1-ATRAP-PBX3 Axis Promote Breast Cancer Glycolysis and Malignant Phenotype by Activating AKT/mTOR Signaling

Angiotensin II type 1 receptor-associated protein (ATRAP) is widely expressed in different tissues and organs, although its mechanistic role in breast cancer remains unclear. Here, we show that ATRAP is highly expressed in breast cancer tissues. Its aberrant upregulation promotes breast cancer aggressiveness and is positively correlated with poor prognosis. Functional assays revealed that ATRAP participates in promoting cell growth, metastasis, and aerobic glycolysis, while microarray analysis showed that ATRAP can activate the AKT/mTOR signaling pathway in cancer progression. In addition, ATRAP was revealed to direct Ubiquitin-specific protease 14 (USP14)-mediated deubiquitination and stabilization of Pre-B cell leukemia homeobox 3 (PBX3). Importantly, ATRAP is a direct target of Upstream stimulatory factor 1 (USF1), and that ATRAP overexpression reverses the inhibitory effects of USF1 knockdown. Our study demonstrates the broad contribution of the USF1/ATRAP/PBX3 axis to breast cancer progression and provides a strong potential therapeutic target.

Automated summary

This study discovers that angiotensin II type 1 receptor-associated protein is highly expressed in breast cancer tissues and promotes aggressiveness by promoting cell growth, metastasis, and aerobic glycolysis. It also plays a crucial role in regulating the deubiquitination and stabilization of Pre-B cell leukemia homeobox 3 through ubiquitin-specific protease 14. Furthermore, it is identified as a direct target of upstream stimulatory factor 1 and its overexpression can reverse the inhibitory effects of upstream stimulatory factor 1 knockdown.